← All stocks

BeOne Medicines Ltd.

ONC Mostly scheduled
CIK 0001651308 #603 in the set updated 17 Sep 2026
Bought (12 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$361.20M
$136.75M on a plan · $208.86M straight out of an exercise
Sold at will
$15.59M
55 of 192 sales
Net
−$361.20M
−$15.59M against sales at will

By person

18 insiders · 192 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
OYLER JOHN
Chief Executive Officer
$327.88M (121) scheduled
−$327.88M
5,697,649
$2.00B
Wang Xiaodong
Director
$13.37M (8) scheduled
−$13.37M
4,588,163
$1.61B
−10.9%
Wu Xiaobin
President and COO
$8.75M (19)
−$8.75M
1,308,161
$459.50M
+74.4%
Lee Chan Henry
SVP, General Counsel
$7.95M (22) scheduled
−$7.95M
346,554
$121.73M
+161.1%
Wang Lai
President, Global Head of R&D
$1.17M (5)
−$1.17M
1,710,085
$600.67M
+96.8%
Sanders Corazon (Corsee) D.
Director
$961.17K (3) scheduled
−$961.17K
57,226
$20.10M
+23.2%
Rosenberg Aaron
Chief Financial Officer
$524.45K (2)
−$524.45K
397,891
$139.76M
+306.6%
BAKER BROS. ADVISORS LP entity
Director
$261.98K (4)
−$261.98K
8,229,961
$2.89B
−17.1%
Ball Titus B.
Principal Accounting Officer
$127.34K (5)
−$127.34K
97,929
$34.40M
+159.0%
Dugan Margaret
Director
$65.64K (1)
−$65.64K
73,164
$25.70M
+68.5%
Riva Alessandro
Director
$65.62K (1)
−$65.62K
73,164
$25.70M
+68.5%
Yi Qingqing
Director
$65.60K (1)
−$65.60K
27,326
$9.60M
−40.8%
HHLR ADVISORS, LTD. entity
10% owner
125,045,741
$43.92B
−12.5%
HOOPER ANTHONY C
Director
83,720
$29.41M
+55.7%
BRANDICOURT OLIVIER
Director
46,306
$16.27M
+183.4%
Sharp Shalini
Director
38,116
$13.39M
Sawyers Charles Lazelle
Director
18,984
$6.67M
+474,500%
Mooney Elizabeth Fisher
Director
18,980
$6.67M

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.

Nothing of that kind in this period.

What was left out

Form 4 filings counted 67
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 2
Sales on a Rule 10b5-1 plan 54
Sales straight out of an exercise 83
Sales at will 55
Transactions with no price 0
Shares from compensation/vesting 4,398,908
History held since 7 Sep 2016